This case reveals the possible survival benefit of immunotherapy after multiple lines treatment in ALK-positive advanced lung adenocarcinoma, suggesting it is possible to find new therapeutic targets based on NGS molecular detection and provide precise therapeutic strategies for clinical practice when drug resistance or progression occurs in cancer therapy. This evidence concerns the gene ALK and lung adenocarcinoma.